Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting financial results for first quarter 2024, the period ended March 31, 2024. Highlights of the report show the company saw record first-quarter revenues of an estimated $14 .6 million, a 28% increase over revenues reported in the first quarter of 2023, as well as growth in its contract services space. The report also noted that during Q1 2024, Progressive Care began ramping up additional sales and marketing activities targeting the long-term care market in South Florida. “First-quarter results clearly demonstrate the continued positive momentum in our business, highlighted by considerable growth in our 340B contract services segment,” said Progressive Care CEO and chair Charles M. Fernandez in the press release. “Our ability to deliver highly specialized care for patients and create enhanced value for providers remains critical to our success, attributes we believe will allow us to further expand our long-term care and OTC business going forward. Furthermore, through the recently proposed merger with NextPlat Corp. (NASDAQ: NXPL), we believe that Progressive Care will have the opportunity to leverage additional capabilities and resources, further supporting its growth into new and existing healthcare markets throughout the remainder of 2024 and beyond.”
To view the full press release, visit https://ibn.fm/ahUMU
About Progressive Care
Progressive Care, through its subsidiaries, is a Florida health services organization and provider of third-party administration (“TPA”), data management, COVID-19-related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, provider of telepharmacy services, the sale of anti-retroviral medications, medication therapy management (“MTM”), the supply of prescription medications to long-term care facilities, and health practice risk management. Progressive Care became a subsidiary of NextPlat Corp. (NASDAQ: NXPL) on July 1, 2023. For more information about the company, visit www.ProgressiveCareUS.com
NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
